DE4207657A1 - Medical adhesive containing di:sulphide pharmaceutical - comprises adhesive base of ABA block copolymer, sticky material, oil, hydrophilic polymer and water - Google Patents

Abstract

A medical adhesive consists of foundation (A) based on an ABA-block copolymer, a sticky-making component, an oil component, a hydrophilic polymer and water, into which has been worked (B) a disulphide bond contg. medicinal active ingredient. USE/ADVANTAGE - The medical adhesive does not contain any components which would deactivate a medicament contg. disulphide bonds. The disulphide bond contg. component is stable in the adhesive, which has a long-lasting high degree of adhesiveness, ensures percutaneous absorption, has long-lasting analgesic/antiinflammaotry action, is capable of taking up water and does not lose its adhesiveness on transcription. There are not significant side effects and the cooling effect of water is utiliseent

Description

The present invention relates to a medical Adhesive that is free from deactivation of a Disulfide bond-containing medicinal ingredient is.

To alleviate the symptoms caused by vitamin B ₁ deficiency, such as neuralgia, myalgia, arthralgia and physical fatigue, it is common practice to administer an analgesic / anti-inflammatory agent parenterally or orally. However, injections are associated with pain, while oral medication tends to cause side effects such as nausea, heartburn, epigastric discomfort and so on. To alleviate such symptoms, topical preparations for topical application may be indicated with advantage.

From such external preparations are ointments, creams, Lotions etc. well suited for local applications, cause however the problem of a variation of the Application amount as well as the trouble, pollution of the worn clothing by occlusion bandages or to prevent such.  

On the other hand, medical adhesives make the Ab absorption of a drug substance at the site of its users tion by means of a simple procedure and yet with a reduced risk of the above-mentioned side effects effects for sure. Known as such medical Adhesives are patches (adhesive tapes) that are free of Are moisture, and cataplasms or packs that are rich in moisture. The taped Plasters are designed to be highly adhesive so that they are not easy from the place of application be removed, even then, when moving on parts of the body. For this Reason it often happens that when removing a Plasters pulled the body hairs at the place of application become, which is painful. That's why many medical adhesives, the analgesic / anti Contain inflammatory drugs, in the form of a Cataplasmas available, awaiting the cooling Effect of the water contained therein and the lightness the diffusion of the drug through the skin.

In an aqueous solution of one or more, the base for such cataplasm forming raw materials (eg. Gelatin, starch, agar, carboxymethylcellulose, carboxy vinyl polymer, polyacrylic acid, sodium polyacrylate, Methyl vinyl ether-maleic anhydride copolymer, etc.) suffers the medical ingredient, in particular a a disulfide bond-containing medicinal agent substance such as Fursultiamin, a chemical reaction and will decomposed so quickly that its analgesic / antiinflamma toric effect does not last for a sufficiently long time can be maintained.

JP-OS 1 01 420/1979 discloses a wet dressing (Um On the basis of a water-containing gel, the  by dispersing water in fine droplets in a closed, made of a block copolymer A-B-A and an oil phase existing oil with the help of an emulsifier is produced and a medical drug, about an analgesic / anti-inflammatory agent in the Base contains, with the water droplets about 5 to Make up 70% by weight of the total composition. If however, a disulfide bond-containing, med shear drug in such a base of an envelope is incorporated, the active ingredient is deactivated, such as mentioned above, so that the desired analgesic / anti-inflammatory effect does not have a sufficient long lasting can be achieved. In addition, there is a risk that the wet dressing an aging of its stickiness suffers and with it too the effect of transdermal diffusion of the med loss of active substance. There continue to be one medical adhesive by dispersing Water droplets available by means of an emulsifier is absent, the water absorbency exists as well the tendency for transpiration to cause the Easily change from the location of its application replaces. The ease with which the adhesive is used Glueing loses, also means another Loss of efficacy of percutaneous intake of medical drug.

JP-OS 2 12 429/1984 discloses a cataplasm, the A-B-A block copolymers containing base polymer and an oil or a higher fatty acid than an emollient Agent, an aqueous solution of a hydrophilic polymer, a hydrophilic polymer, a polyhydric alcohol and water and dispersed in the base polymer is, and includes a medicinal agent. If  however, a disulfide bond-containing medical grade shear drug used in the above cataplasm is the active ingredient is deactivated, so that pharmacological effect does not have a sufficient can be maintained for a long time.

For this reason, it is an object of the invention to provide a to provide a high quality medical adhesive Stability of a disulfide bond-containing medical drug and a long-lasting high Degree of adhesion and percutaneous absorption ensures.

It is another object of the invention to provide a medical provide a long-lasting ensures analgesic / anti-inflammatory effect.

Yet another object of the invention is to provide a to provide medical adhesive, the water is capable of seizure and on transpiration its adhesion do not lose.

The inventors of the present invention have exhaustive Investigations performed to those designated above To achieve goals; they have found that in a specially formulated basis a disulfide Binding-containing medicinal active stable remains and that such an adhesive produced is able to remarkably mention the said Symptoms without the risk of side effects and doing the above-mentioned cooling effect of the water exploit. The present invention was based on Based on the above findings developed.  

Accordingly, the present invention makes a medical adhesive, which is an A-B-A Block copolymer, a tackifier, an oil component te, a hydrophilic polymer and water-containing base and, incorporated into this, a disulfide bond comprising medicinal active ingredient.

In said block copolymer, block A denotes a hard polymer unit such as polystyrene, during the Block B is a soft polymer unit such as polybutadiene, Polyisoprene or the like. To the block copoly include, inter alia, styrene-isoprene-styrene Block copolymers.

The tackifiers include, among others, rosin and its derivatives, petroleum hydrocarbon resins and the corresponding hydrogenated resins, coumarone resins, Terpene resins and phenolic resins. The oil component comprises in addition to other, liquid rubber, paraffin oil, naph then oil and waxes.

The hydrophilic polymer retains water and is combined men dispersed with water without the aid of an emulsifier. The hydrophilic polymers include both water soluble as well as water swellable polymers (high graded water-accepting polymers). As examples of such polymers are mentioned are different wasserlösli polymers such as gelatin, mannan, various gums, Starch derivatives, cellulose derivatives, poly (vinyl alcohol), Poly (ethylene oxide), polyacrylic acid salts, alginic acid Salts, acrylic polymers, etc., and copolymers thereof, which water swellable polymers.

The approximate ratios of these components in the Base are: 5 to 40% by weight of A-B-A block copolymer, 10  to 50% by weight of tackifier, from 5 to 30% by weight of oil compo nenten, 0.1 to 10 wt .-% of hydrophilic polymer and 1 to 40% by weight of water.

The base may contain an antioxidant in a quantity Contain about 0.01 to 2 wt .-%.

Incorporated into the base of the above composition is a disulfide bond-containing medicinal agent such as an active vitamin B ₁ derivative or a salt thereof. The medicinal agent includes those compounds which are readily available from the skin, but are susceptible to being deactivated in the conventional art, such as thiamine tetrahydrofurfuryl disulfide or its salts. When the medicinal agent is formulated in this way with the specific base described above, it can remain stable for a long period of time. The proportion of the medicinal agent in the base may be, for example, about 0.01 to 10% by weight.

Also other drug agents and additives can be included in the base.

Fig. 1 is a diagram showing the results obtained in Examples and Comparative Example.

Fig. 2 is a graph showing the results of the control experiment in the Experimental Example.

Fig. 3 is a graph showing the results of the application of the medical adhesive of the comparative example in the Experimental Example.

Fig. 4 is a graph showing the results of the application of the medical adhesive of Example 1 in the Experimental Example.

The block A of the block copolymer ABA contained in the base is a hard polymer unit, and the block B thereof is a soft polymer unit. Mentioned as examples of the block A are polymers of vinyl compounds Ver such as an aromatic vinyl compound, eg. Styrene, methylstyrene and so on. The block B may be a polymer of a conjugated diene compound such as butadiene, isoprene and so on. The molecular weight of the block A may be, for example, about 1000 to 50 × 10⁴, while the molecular weight of the block B may be, for example, about 5000 to 20 × 10 ⁴ . Preferred block copolymers include a styrene-butadiene-styrene block copolymer and a styrene-isoprene-styrene block copolymer. Particularly preferred is a styrene-isoprene-styrene block copolymer.

The amount proportion of the A-B-A block copolymer in the Base is about 5 to 40 wt .-%, and preferably about 5 to 25% by weight. When the block copolymer is less than 5 wt .-%, it lacks the finished preparation Elasticity and cohesiveness and consequently Dimensional accuracy while using the block copolymer in an amount exceeding 40% by weight tends to increase cause it to stick to the finished product and stickiness is missing.  

The tackifier can be any of the various types Substances that are common in adhesive-together be used. As such sticky Preparing agents may include rosin and its derivatives be mentioned, such as rosin itself, hydrogenated Rosin products whose esters are polyvalent Alcohol, for example ester gums; Petroleum Coal hydrogen resins such as synthetic polyterpene resins, aromatic hydrocarbon resins, aliphatic Hydrocarbon resins, alicyclic saturated carbon Hydrogen Petroleum Resins, Dicyclopentadiene Resin, etc. and the corresponding hydrogenated resins; Coumarone resins like Cumaron-inden resin; Terpene resins such as terpene phenolic Resin, polyterpene resin etc., phenolic resins and so on. These tackifiers can be used alone or in Combination can be used.

The proportion of the tackifying agent in the base be carries about 10 to 50 wt .-% and preferably about 15 to 40% by weight. When the proportion of the tackifier is less than 10% by weight, the tackiness of the fer inadequate during use of the drug tackifier in an amount greater than 50% by weight the tendency is favoring the finished preparation hard make and minimize its adhesive strength.

The oil component includes, inter alia, liquid Rubber types such as liquid polybutadiene, liquid Polybutene, liquid polyisoprene, liquid polyisobutene len, depolymerized rubber, etc .; Oils like the ones in the paraffin or naphthen series; and waxes like Paraffin wax, carnauba wax, microcrystalline wax, Beeswax, polyethylene and so on.  

The proportion of said oil component in the Base is about 5 to 30 wt .-%, and preferably about 5 to 25% by weight. If the proportion of oil is less than 5 wt .-%, the finished preparation is in his detention inadequate. Conversely, if the oil component in is present in an amount of more than 30 wt .-%, is the Cohesive power of the finished preparation bad, and it There is a tendency to make the skin sticky after removing it leave.

The hydrophilic polymer for use according to the invention The term includes both water-soluble polymers and with Water swellable polymers (strongly water-absorbing Polymers). Thus, among the hydrophilic polymers water-soluble polymers such as gelatin, mannan, various dene gums, starch derivatives (eg grafted with starch acrylate copolymer), cellulose derivatives such as carboxy methylcellulose, poly (vinyl alcohol), poly (ethylene oxide), Polyacrylic acid salts and other acrylic polymers, algin acid salts, etc. as well as water swellable polymers, which include their copolymers. Particularly preferred Poly (vinyl alcohol), starch derivatives, poly (ethylene oxide), Gums and copolymers thereof. Such with water swellable copolymers assets due to the inclusion to swell from a lot of water. As such polymers can those who are about 5 to 2000 times their Own weight to absorb water, are used. To particularly preferred polymers include water-soluble Polymers, in particular polyvinyl alcohol. The water-soluble polymers and water-swellable polymers can be used independently or in combination be set.

Due to the use of such a hydrophilic polymer Water is dispersed in such a way that it through the  Polymer without the aid of a surfactant for dispersion and emulsification of the water is recorded. by virtue of it is now possible, not just a decrease the stickiness and a detachment of the finished preparation as a result of transpiration from the site of its application but also the percutaneous intake of the reinforce medical drug.

Type and amount of such a hydrophilic polymer with regard to the stability of the medical effect fabric selected. The proportion of the hydrophilic polymer may for example be 0.1 to 10 wt .-%. If the Content is less than 0.1 wt .-%, the water content becomes property of the finished preparation sacrificed while the Preparation tends to be a hard consistency when the Content of hydrophilic polymer exceeds 10% by weight.

The water content in the base is about 1 to 40 wt .-%, preferably about 5 to 35 wt .-% and for even better results about 10 to 30 wt .-%. If the Water content is less than 1 wt .-%, the Cooling effect of the water and the effectiveness of the remedy medium levy impaired. On the other hand, if the Water content is more than 40 wt .-%, the growing Tendency towards an inadequate Adhesiveness of the preparation.

For the purpose of strengthening the stability of the base and The medical drug may be an antioxidant be incorporated into the base. The anti Oxidizer can be any one, the oxidation be inhibitory substance capable of decomposing and to inhibit the aging of the base. Accordingly, among the Antioxidants, among others, alkylphenol  Compounds such as 2,6-di-t-butyl-p-cresol (BHT); alkylene bisphenol compounds such as 2,2'-methylenebis (4-methyl) 6-t-butylphenol); Thiopropionic acid esters such as dilauryl 3,3'-thiodipropionate; Phosphorus compounds such as nonyl phenyl phosphite; Amine compounds such as N-phenylnaphthyl amine; and so on.

The amount of antioxidant should be enough to a discoloration of the base and the finished preparation and to prevent aging of adhesiveness, and may for example be about 0.01 to 2 wt .-%.

Furthermore, the base may have other known ingredients such as percutaneous absorption-promoting agents, oils, Liquid paraffin, lanolin, coloring agents, maskie agent, pH adjuster, stabilizer gates, preservatives and extenders such as titanium dioxide, kaolin, bentonite and so on.

The basis of the above composition behaves as a water-based hot melt adhesive and provides both the Cooling effect of the water as well as the long-term resistance speed of the medical drug. For this reason can the adhesiveness of the base and the medizi nische active ingredient containing finished preparation and thus a high degree of percutaneous admission of the medical Active ingredient for a sufficiently long time upright to be obtained.

In the medical adhesive of the invention, the disulfide bond-containing medicinal agent is incorporated in the above base. The medical active substance may be any compound having a disulfide bond. The preferred medicinal agent is one having analgesic / anti-inflammatory activity. Preferred examples of such a medicinal agent are active vitamin B ₁ derivatives and their salts such as thiamine propyl disulfide (TPD), thiaminetetrahydrofurfuryl disulfide (Fursultiamin, TTFD), thiamine-6-methoxycarbonyl-l-acetylthiopentyl disulfide (TATD) and their salts and so on. Particularly suitable are TTFD and its salts. The hydrochloride of TTFD can be represented by the following structural formula.

As salts of such an active vitamin B ₁ derivative may be mentioned inorganic salts such as hydrochloride, sulfate, nitrate, phosphate, etc .; Salts with hydrohalic acids such as hydrofluoride, hydrobromide, etc .; lower alkanesulfonates such as methane sulfonate, trifluoromethanesulfonate, ethanesulfonate, etc .; Arylsulfonates such as benzenesulfonate, p-toluenesulfonate, etc., and salts of various organic acids such as fumarate, succinate, citrate, tartrate, oxalate and so on.

The active vitamin B ₁ derivatives and salts alleviate various symptoms associated with vitamin B ₁ deficiency states, such as neuralgia, myalgia, arthralgia, and physical fatigue. These drugs have heretofore been formulated as injections and tablets for parenteral or oral administration, but it is not known that these compounds can be administered transdermally in therapeutically effective doses. Moreover, because they are in danger of being deactivated in the usual ointment or other bases, there is no available medical adhesive containing any of these agents in a base.

When the medicinal agent is incorporated into the base tet, it can be kept stable, and its analgesic / anti-inflammatory effect can be long time be maintained. If desired, two or more types of such medicinal agents in the be incorporated according to the invention base.

The proportion of the medicinal agent in the base is not critical, but it is generally in the Range of about 0.01 to 10 wt .-%.

The medical adhesive according to the invention may be such contain other drug agents, like them commonly used in cataplasms or the like such as l-menthol, d, l, camphor, methyl salicylate, Glycol salicylate, vanillyl nonylamide, powdered Phellodendron, Capsicum extract, Diphenhydramine-hydro chloride, chlorphenyramine maleate, ammonium glycyrrhetinate, Vitamin E and so on. The proportion of such supplementary Drugs agents is not critical, but be it generally carries about 0.01 to 10 wt .-%.

The medical adhesive of the invention can be used with the aid of per se known procedures are produced. On typical manufacturing process involves melting the A-B-A block copolymer, tackifier and oil Component with mixing and heating, preferably  at about 120 ° C to 180 ° C, and after lowering the Temperature of the melt, dispersing the hydro philen polymer, water and a medical Active ingredient in the same. The water is preferably in Form of an aqueous solution of the polymer or a Water-containing water-absorptive polymer added give. The medicinal ingredient can be used together with the hydrophilic polymer and the water or after the addition of the hydrophilic polymer and water become. The antioxidant, oily additives and Other oily drug agents can generally NEN together with the block copolymer, etc. under heating or, if necessary, after lowering the Temperature of the melt to be added.

For the melt-blending operation, a Banbury mixer, a kneader or the like can be used. For the addition and dispersion of the hydrophilic polymer, the water and the medicinal agent into the cooled mass, a high speed mixer is preferably used, such as a high speed mixer, a colloid mill, an emulsifier, an ultrasonic emulsifier or similar. The process of mixing at high speed can at a temperature of about 50 ° C to 100 ° C, preferably from about 75 ° C to 90 ° C, and a rotational speed of about 1,000 to 30,000 min ^-1, preferably of about 1200-5000 min ^-1 .

The medical adhesive obtained in this way can directly as analgesic / antiinflammatory Drug will be used, however, the the medizi generic active ingredient in general  the way that they bend as a layer on one same base film is applied, for. B. on a movie or a sheet of a synthetic polymer Fabric material or a nonwoven material, and with a Foil made of a plastic or other material covered, which is derived from the pharmaceutical base can be withdrawn. The flexible base film can be a porous layer around the drug-containing base and include a laminating layer. A a base layer comprising porous layer is preferred. Thus, the preferred medical adhesive comprises a Base film, a pharmaceutical base layer, the contains a disulfide-containing medicinal agent, and a film containing the pharmaceutical base layer covered and allowed to peel off this.

The invention also discloses a method for stabilization sated medicinal agents containing a disulfide bin contained. In this method of stabilization The components are those described above Base with such, a disulfide bond containing medicinal active ingredient mixed.

The following examples are intended to illustrate the invention in detail, but are by no means to be understood that they de fi ren the limits of the invention de. In these examples, all percentages (%) are by weight.

Examples example 1 % A-B-A Block Copolymer [Shell Chemical Co., Ltd., Japan, Styrene-Isoprene-Styrene Block Copolymer, CARIFLEX TR-1107] 17.0 Tackifier [Arakawa Chemical Co., Ltd., Japan, Alicyclic Saturated Hydrocarbon Petroleum Resin, ARKON P-100] 26.0 Oil (Polybutylene Liquid Rubber) [Nippon Petrochemicals Co., Ltd., Japan, HV-300] 15.0 Antioxidants [Nakarai Tesque Co., Ltd., Japan, BHT] 1.0 Water Soluble Polymer [The Nippon Synthetic Chemical Industry Co., Ltd., Japan, poly (vinyl alcohol)] 3.0 Purified water 20.0 TTFD hydrochloride 1.0 glycol salicylate 3.0 l-menthol 3.0 Vitamin E 0.5 Liquid paraffin [Matsumura Petro-Chemical Co., Ltd., Japan, P-70] 10.0 Masking Agent [Sodium Methylenediaminetetraacetate (CLEWAT)] 0.5

Of the above basic components, the A-B-A Block copolymer, the tackifying agent, the liquid rubber, the antioxidant and the Liquid paraffin melted and in a kneader at about 150 ° C mixed. The resulting melt was cooled to about 90 ° C, and glycol salicylate, l-menthol and vitamin E were added. The TTFD, the water soluble polymer and the sequestering agent were incorporated in  Dissolved water, and the resulting aqueous solution was heated to about 70 ° C and in the above kneader in which the entire batch is added by stirring high speed was well dispersed.

The resulting composition containing TTFD was applied while still hot to a nonwoven material at a rate of about 500 g / m ² , and a silicone-coated polyethylene terephthalate film was laminated on the coated base. The laminate was then cut to size to provide a medical adhesive.

Example 2 % A-B-A block copolymer (as in Example 1) 20.0 Tackifier [Yasuhara Oils and Fats Co., Ltd., Japan, Hydrogenated Polyterpene Resin, CLEARON P100] 24.0 Oil (polyisobutylene liquid rubber) [Nippon Petrochemicals Co., Ltd., Japan, TETRAX] 13.0 Antioxidant (as in Example 1) 1.0 Water-soluble polymer (as in Example 1) 2.0 Highly water swellable polymer [Sanyo Chemical Industries Co., Ltd., Japan, starch grafted acrylate copolymer, SANWET] 1.0 Purified water 20.0 TTFD hydrochloride 1.0 glycol salicylate 3.0 diphenhydramine 0.1 Capsicum extract 0.15 Purified lanolin 14.75

Using the above components became medical adhesive prepared as in Example 1.

Example 3 % A-B-A block copolymer (as in Example 1) 16.0 Tackifier [Arakawa Chemical Co., Ltd., Japan, Alicyclic Saturated Hydrocarbon Petroleum Resin, ARKON M-100] 23.0 Oil (polyisoprene liquid rubber) [Kuraray Isoprene Chemicals Co., Ltd., Japan, LIR-50] 14.0 Antioxidant (as in Example 1) 0.5 Water-soluble polymer (as in Example 1) 3.0 Purified water 20.0 TTFD hydrochloride 1.0 glycol salicylate 3.0 d, l-camphor 2.0 Vitamin E 0.5 Liquid paraffin (as in Example 1) 11.0 Titanium dioxide 1.0 kaolin 5.0

Using the above components became medical adhesive prepared as in Example 1.

Comparative example % carboxymethylcellulose 3.0 Carboxyvinyl polymer 8.0 Water-soluble polymer (as in Example 1) 2.0 70 percent strength. sorbitol 20.0 glycerin 30.0 polyacrylic acid 5.0 TTFD hydrochloride 1.0 glycol salicylate 1.0 l-Mehthol 0.5 aluminum hydroxide 0.1 water 29.4

Using the above components, a pharmaceutical composition was prepared in a conventional manner as in Example 1, applied to a nonwoven material at an application rate of 500 g / m ² and cut to the appropriate size to provide a medical adhesive.

The preparations obtained in Examples 1 to 3 and Comparative Example were each placed in a polyethylene / aluminum bag and kept at 40 ° C, and the residual amounts of TTFD were determined by high-performance liquid chromatographs at fixed intervals. The results of this stability test are shown in FIG .

It can be seen from Fig. 1 that the medical adhesives of Examples 1 to 3 are superior in resistance to aging of the TTFD in comparison with the medical adhesive of the comparative example.

Experimental Example

Using an isokinetic machine (Myoret RZ-450, Kawasaki Heavy Industries, Ltd., Japan) to quantitatively apply a training load designed to induce retarded myalgia, a healthy group of 6 volunteer volunteers were exposed to a centrifugal contraction load 800 times Thigh extensor muscle group (quadriceps muscles of the thigh) acted upon. Immediately after the exercise load was applied and at 12, 24 and 36 hours thereafter, two sheets of the medical adhesives of Example 1 and Comparative Example (each 10 cm × 14 cm foil) were applied to the loaded areas. The site of application was 15 cm above the knee joint. The stress experiment without the use of one of the two adhesives served as a control. Using a 1.5 T ¹ H MRI (Magnetic Resonance Imaging) / S system (Gyroscan 515, Phillips), ¹ H-MRI was performed before and after training exercise, and computer-evaluated images of SE, IR , longitudinal relaxation time T ₁ and transverse relaxation time T ₂ were obtained.

In the data analysis, the training load was quantified as the amount of work (watts and joules), and the change in ¹ H MRI before and after training was evaluated. In this way, areas of interest (ROI) were determined, and the relaxation times T ₁ and T ₂ were determined from the changes in the figures. The areas of interest were designated ROI 1 for an area on one side of the cross-section of the application site, ROI 3 for an area of interest on the opposite side, and ROI 2 for a region of interest between the above two lateral areas.

The temporal courses of the relaxation time T ₂ (mean), which is an adequate indication for the decay of muscle fatigue and pain, are shown in Figs. 2-4. Fig. 2 is a graph showing the results of the control experiment. Fig. 3 is a graph showing the results of the application of the medical adhesive of the comparative example, and Fig. 4 is a graph showing the results of the application of the medical adhesive according to the case of game 1 . The relaxation time T ₂ is the time until the nuclear spin system returns to its original state by dissipation of the energy absorbed in radio waves.

From Fig. 2 it is apparent that when only the training ningsbelastung occurred and no medication was made, the maximum relaxation time occurred 24 to 72 hours after the training load and then the relaxation time gradually decreased. In contrast, when the medical adhesives of Comparative Example 1 and Example 1 were used, recovery from muscle fatigue and myalgia occurred earlier, as shown in Figs . In particular, with the medical adhesive of Example 1 containing TTFD, the onset of muscle fatigue and myalgia occurred earlier than was the case with the medical adhesive of the comparative example.

Claims (27)

A medical adhesive comprising an A-B-A block Copolymer, a tackifier, an oil compo nente, a hydrophilic polymer and water comprising Basis and, incorporated into this, a disulfide Binding containing medicinal agent. 2. Medical adhesive according to claim 1, characterized characterized in that the block A of the A-B-A block copolymer is a hard polymer unit and block B is the same is a soft polymer unit. 3. Medical adhesive according to claim 2, characterized marked indicates that block A is a polymer unit Vinyl compounds and block B is a polymer Unit of conjugated dienes is. 4. The medical adhesive according to claim 2, characterized in that the molecular weight of the block A is 1000 to 50 × 10 ⁴ and the molecular weight of the block B is 5000 to 20 × 10 ⁴ . 5. Medical adhesive according to claim 1, characterized characterized in that the block copolymer, a styrene-butadiene Styrene block copolymer, a styrenoprene-styrene block Copolymer or methylstyrene-isoprene methylstyrene block Copolymer is. 6. Medical adhesive according to claim 1, characterized marked characterized in that the block copolymer is a styrene-isoprene styrene block copolymer.   7. Medical adhesive according to claim 1, characterized marked signs that the tackifier is a colopho nium, a colophonium derivative, a petroleum coals Hydrogen resin, a hydrogenated petroleum hydrocarbon fabric resin, a cumarone resin, a terpene resin or a Phenolic resin is. 8. Medical adhesive according to claim 7, characterized signs that the tackifier is an alicyclic beautiful saturated hydrocarbon petroleum resin or is a hydrogenated polyterpene resin. 9. Medical adhesive according to claim 1, characterized marked characterized in that the oil component is a liquid rubber, a paraffin oil, a naphthenic oil or a wax. 10. Medical adhesive according to claim 1, characterized characterized in that the hydrophilic polymer is a water-soluble Polymer and / or a water-swellable polymer, which is swellable with water. 11. Medical adhesive according to claim 1, characterized marked characterized in that the hydrophilic polymer is a water-soluble Polymer is that made of gelatin, mannan, gums, Starch derivatives, cellulose derivatives, poly (vinyl alcohol hol), poly (ethylene oxide), polyacrylic acid salts, alginate acid salts, acrylic polymers existing group is selected or is a water-swellable polymer, which comprises their copolymers. 12. Medical adhesive according to claim 1, characterized marked characterized in that the hydrophilic polymer is selected from the group consisting of poly (vinyl alcohol), (starch derivatives, poly (ethylene oxide), Gummen and their copolymers existing group is selected.   13. Medical adhesive according to claim 1, characterized characterized in that the hydrophilic polymer is poly (vinyl alcohol) contains. 14. A medical adhesive according to claim 1, characterized in that the medicinal active ingredient with a disulfide bond is an active vitamin B ₁ derivative or a salt thereof. 15. A medical adhesive according to claim 14, characterized in that the active vitamin B ₁ derivative or the salt thereof is selected from the group consisting of Thiaminpropyldisulfid, Thi amintetrahydrofurfuryldisulfid and thiamin-6-methoxy carbonyl-acetylthiopentyldisulfid and their salts. 16. The medical adhesive according to claim 14, characterized in that the active vitamin B ₁ derivative or the salt thereof thiamine tetrahydrofurfuryl disulfide or a salt thereof. 17. Medical adhesive according to claim 16, characterized ge indicates that the thiamine tetrahydrofurfuryl disulfide Salt is thiamine tetrahydrofurfuryl disulfide hydrochloride. 18. Medical adhesive according to claim 1, characterized marked characterized in that the base comprises from 5 to 40% by weight of an A-B-A Block copolymer, 10 to 50 wt .-% of a tackifying the agent, 5 to 30 wt .-% of an oil component, 0.1 to 10% by weight of a hydrophilic polymer and 1 to 40 wt .-% water and a medicinal agent with a disulfide bond is included in this base worked.   19. A medical adhesive according to claim 18, characterized ge indicates that the proportion of eingear in the base processed medical active substance 0.01 to 10% by weight is. 20. Medical adhesive according to claim 1, characterized records that the base ent entanti antioxidant holds. 21. Medical adhesive according to claim 20, characterized ge indicates that the proportion of the antioxidant in the base 0.01 to 2 wt .-% is. 22. Medical adhesive according to claim 1, characterized marked records that the base continues to have at least one compo containing l-menthol, d, l-camphor, Methyl salicylate, glycol salicylate, vanillylnonylamide, powdered phellodendron, capsicum extract, diphene hydramine hydrochloride, chlorphenyramine maleate, ammonium glycyrrhetinate and vitamin E group is selected. 23. A medical adhesive comprising a base, the one Styrene-isoprene-styrene block copolymer, a sticky making agent, a liquid rubber, an anti oxidizing agent, poly (vinyl alcohol) and / or a with Water swellable polymer and water includes, and a a disulfide bond-containing medicinal agent fabric incorporated in the base. 24. Medical adhesive according to claim 23, characterized ge indicates that the base consists of 5 to 40 wt .-% of a Styrene isoprene-styrene block copolymer, 10 to 50% by weight a tackifying agent, 5 to 30% by weight of a  liquid rubber, 0.01 to 2 wt .-% of an antioxidant agent, 0.1 to 10 wt .-% of a poly (vinyl alcohol) and / or a water-swellable polymer and 1 to 40 wt .-% water and the medical Active substance with a disulfide bond in a proportion of 0.01 to 10 wt .-% is contained in the base. 25. A medical adhesive according to claim 23, characterized in that the medicinal active ingredient having a disulfide bond is an active vitamin B ₁ derivative or a salt thereof. 26. Medical adhesive according to claim 23, characterized ge indicates that the medicinal agent with a Disulfide bond thiamine tetrahydrofurfuryl disulfide or a salt thereof. 27. Medical adhesive comprising a foundation Foil, a pharmaceutical base layer containing a medical drug with a disulfide bond ent holds, and a foil that covers this base layer and lets himself be pulled off.